CAR-NK cell therapy: promise and challenges in solid tumors.

Front Immunol · 2025 · PMC12009813 · PMID 40260240

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a notable trendno p-value reported

A notable trend is the expanding focus on solid tumors, with trials employing novel targets like Claudin6 ( NCT05410717 ), mesothelin (ChiCTR2100048100), and DLL3 ( NCT05507593 ).

also in 2,380 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.